Conflict of interest: Nothing to declare.
Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience
Version of Record online: 1 APR 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 8, pages 1376–1381, August 2014
How to Cite
Song, B. S., Seo, J., Kim, D. H., Lim, J. S., Yoo, J. Y. and Lee, J. A. (2014), Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr. Blood Cancer, 61: 1376–1381. doi: 10.1002/pbc.25035
- Issue online: 10 JUN 2014
- Version of Record online: 1 APR 2014
- Manuscript Accepted: 25 FEB 2014
- Manuscript Received: 24 DEC 2013
We evaluated the efficacy of gemcitabine and docetaxel chemotherapy (GEM + DOC) in children and adolescents with recurrent or refractory osteosarcoma.
Data of 28 patients (20 male, 8 female) who received gemcitabine (675 or 900 mg/m2 on days 1 and 8) and docetaxel (100 mg/m2 on day 8) at Korea Cancer Center Hospital were retrospectively reviewed.
Patients (ages 5.0–19.7 years) received a total of 96 courses of chemotherapy (median 3 courses; range, 1–8 courses) and were followed for a median of 14.9 months (range, 0.6–81.4 months). Eleven patients received GEM + DOC after surgery as adjuvant chemotherapy. Seventeen patients received GEM + DOC as palliative therapy, and were eligible for response evaluation; there were three (17.6%) complete response (CR, including two metabolic CR), one (5.9%) partial responses (PR), and three (29.4%) stable disease (SD). The objective response rate (CR + PR) and tumor control rate (CR + PR + SD) were 23.5% and 41.2%, respectively. The median duration of response was 11.2 months (range, 2.8–14.6 months). Dose of gemcitabine (675 or 900 mg/m2) did not influence the response rate. Overall survival at 1-year was 53.6 ± 9.4% and patients who received GEM + DOC as adjuvant chemotherapy fared better than those who received GEM + DOC as palliative therapy (72.7 ± 13.4% vs. 35.3 ± 11.6%, P = 0.006).
GEM + DOC showed some activity in osteosarcoma. Better than expected survival after GEM + DOC was seen both in patients with and without surgery. These results may indicate that dose dense combinations of gemcitabine and taxanes (e.g., gemcitabine + nab-paclitaxel) should be investigated in bone sarcomas. Pediatr Blood Cancer 2014; 61:1376–1381. © 2014 Wiley Periodicals, Inc.